Drug
Iso-sulfan blue clinical trials
Also written isosulfan blue and Lymphazurin.
- studies test it
- 8
- open now
- 0
- in phase 3
- 0
- first study started
- 1997
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2004 (3)
| Year | Studies |
|---|---|
| 1997 | 1 |
| 1999 | 1 |
| 2004 | 3 |
| 2005 | 1 |
| 2013 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 0 · Other 8
Ohio State University Comprehensive Cancer Center (1) · University of Miami (1) · NYU Langone Health (1) · Roswell Park Cancer Institute (1) · M.D. Anderson Cancer Center (1) · Case Comprehensive Cancer Center (1) · Gynecologic Oncology Group (1) · Saint John's Cancer Institute (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses iso-sulfan blue is read from its arms, and is right about nine times in ten.
Testing it · 8
- Lymph Node Mapping in Patients With Endometrial CancerCompletedNot applicableOhio State University Comprehensive Cancer CenterNCT01818739Written as isosulfan blue
- Lymph Node Mapping in Patients With Newly Diagnosed Endometrial Cancer Undergoing SurgeryTerminatedNot applicableCase Comprehensive Cancer CenterNCT01939028Written as isosulfan blue
- Lymph Node Mapping and Sentinel Lymph Node Identification in Patients With Stage IB1 Cervical CancerTerminatedNot applicableGynecologic Oncology GroupNCT00070317Written as Isosulfan Blue
- Thoracoscopic Sentinel Lymph Node Biopsy in Patients With Stage I or Stage II Breast CancerCompletedNot applicableUniversity of MiamiNCT00450723Written as Isosulfan blue
- Lymphoscintigraphy to Detect Early Metastases in Patients With Cancer of the Mouth or ThroatCompletedNot applicableNYU Langone HealthNCT00012168Written as isosulfan blue
- Lymphatic Mapping, Sentinel Lymph Node Analysis, and Blood Tests in Detecting and Predicting Early Micrometastases in Patients With Colorectal CancerStatus unknownPhase 2Saint John's Cancer InstituteNCT00625625Written as isosulfan blue
- Diagnostic Procedure for Identifying Patients With Metastatic Colorectal CancerCompletedNot applicableRoswell Park Cancer InstituteNCT00003186Written as isosulfan blue
- Injection Methods in Finding the Sentinel Lymph Node During Lymphatic Mapping and Sentinel Lymph Node Biopsy in Patients With Invasive Breast CancerCompletedNot applicableM.D. Anderson Cancer CenterNCT00438477Written as Isosulfan Blue
Given in every arm · 4 — iso-sulfan blue is usual care beside what is tested
- Axillary Reverse Mapping in Preventing Lymphedema in Patients With Breast Cancer Undergoing Axillary Lymph Node DissectionActive, not recruitingPhase 3Alliance for Clinical Trials in OncologyNCT03927027Written as Isosulfan Blue
- A Study of Lymphoseek® as a Lymphoid Tissue Targeting Agent in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node MappingCompletedPhase 2Cardinal Health 414, LLCNCT02509598Written as Vital Blue Dye (optional)
- Pilot Indocyanine Green Imaging for Mapping of Arm Draining Lymphatics & Nodes in Breast CancerCompletedPhase 2Stanford UniversityNCT01771666Written as Isosulfan blue
- Lymph Node Mapping Using Indocyanine Green Solution in Diagnosing Patients With Malignant MelanomaCompletedNot applicableStanford UniversityNCT01898403Written as Isosulfan blue (ISB)
Codes
What other systems call iso-sulfan blue · ClinicalTrials.gg INT002819
- MeSH (NLM) C025484iso-sulfan blueOne source NLM
- UNII (FDA) 39N9K8S2A4ISOSULFAN BLUEConfirmed FDA, NLM
- RxNorm 27863One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C025484 | iso-sulfan blue | One source NLM |
| UNII (FDA) | 39N9K8S2A4 | ISOSULFAN BLUE | Confirmed FDA, NLM |
| RxNorm | 27863 | — | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.